What is pau d'arco used for?

Pau d'arco is traditionally used as an antifungal, anti-inflammatory, and antimicrobial agent, primarily prepared as a tea from the inner bark of Tabebuia impetiginosa. Its key compounds—lapachol and beta-lapachone—have shown activity against Candida, Aspergillus, Staphylococcus, and Helicobacter pylori in laboratory studies, and preliminary human observations suggest possible benefit for oral mucositis and menstrual pain. However, no well-designed clinical trials confirm efficacy for any of these uses in humans.

Is pau d'arco safe to drink as a tea?

Safety at typical tea doses (1–3 cups daily from 2–4 g inner bark) has not been established in controlled human studies, meaning neither confirmed safety nor acceptable risk thresholds are available. At higher doses, lapachol causes documented adverse effects including nausea, vomiting, diarrhea, dizziness, and internal bleeding. Pau d'arco should be avoided in pregnancy, during lactation, and by individuals taking blood thinners due to plausible anticoagulant interactions.

What is lapachol and what does it do?

Lapachol is a naphthoquinone compound found in the inner bark of Tabebuia impetiginosa and is considered the primary bioactive constituent of pau d'arco. In laboratory settings, it inhibits DNA and RNA synthesis in bacteria, fungi, and viruses, and has demonstrated antitumor activity in animal models. Despite promising preclinical data, lapachol showed no clinical benefit in a human trial of chronic myelocytic leukemia patients, and its therapeutic window is narrow due to dose-dependent toxicity.

How do you prepare pau d'arco tea?

Authentic pau d'arco tea is made by simmering 1–2 teaspoons (2–4 g) of the dried inner bark (phloem) in approximately 500 mL of water for 20 minutes, then straining and consuming 1–3 cups per day. It is important to use inner bark only—products containing the full bark with outer layers and heartwood have substantially lower concentrations of active naphthoquinones such as lapachol and beta-lapachone. Methanolic extracts and standardized syrups provide higher phenolic content than aqueous teas but are less traditional and lack dosing guidelines from clinical trials.

Does pau d'arco interact with any medications?

Formal drug interaction studies for pau d'arco have not been published, but lapachol's structural similarity to vitamin K antagonists creates a plausible risk of enhanced anticoagulant effect when combined with warfarin or other blood thinners, potentially increasing bleeding risk. Beta-lapachone's immunomodulatory activity may theoretically interfere with immunosuppressive medications used in organ transplantation or autoimmune disease management. Individuals on any anticoagulant, antiplatelet, or immunosuppressive therapy should consult a healthcare provider before using pau d'arco in any form.

What does the research actually show about pau d'arco's effectiveness in humans?

While pau d'arco demonstrates promising antifungal and antimicrobial activity in laboratory studies against Candida, Aspergillus, and Staphylococcus aureus, clinical trials in humans are notably absent or limited. Most evidence comes from in vitro studies, which do not directly translate to real-world effectiveness in the human body. More rigorous human studies are needed to establish whether pau d'arco delivers the benefits suggested by its traditional use and laboratory findings.

Is pau d'arco safe during pregnancy and breastfeeding?

Pau d'arco is not recommended during pregnancy or breastfeeding due to insufficient safety data and the presence of lapachol, which may have uterine stimulant properties. Pregnant and nursing women should consult a healthcare provider before using pau d'arco in any form. The lack of clinical studies in these populations makes it prudent to avoid use until safety is better established.

Why is pau d'arco more effective as a tea or decoction than other forms?

Pau d'arco's active compounds, particularly lapachol and beta-lapachone, are better extracted through hot water decoction, which helps dissolve these naphthoquinones from the inner bark. Capsules or tablets may contain inconsistent amounts of active compounds and may not deliver the same extraction efficiency as traditional brewing methods. Decoction (simmering the bark) is considered the most traditional and potentially most bioavailable preparation method for accessing pau d'arco's active constituents.

Pau d'Arco

Pau d'Arco contains naphthoquinones—primarily lapachol and beta-lapachone—that inhibit microbial DNA/RNA synthesis, downregulate COX-2 and telomerase, and activate the Nrf2 antioxidant pathway. Human clinical evidence remains limited and inconclusive, with preliminary data suggesting possible benefits for oral mucositis prevention in radiotherapy patients and pain reduction in primary dysmenorrhea, but no robust randomized controlled trial data confirm efficacy or safe dosing.

Category: South American Evidence: 1/10 Tier: Preliminary

Origin & History

Pau d'Arco is derived from the inner bark (phloem) of Tabebuia impetiginosa, a large flowering tree native to the tropical and subtropical rainforests of Central and South America, particularly Brazil, Argentina, Paraguay, and Bolivia. The tree thrives in humid, warm climates at low to mid elevations and is commonly found along riverbanks and forest edges. Traditionally cultivated and wildcrafted by indigenous communities, the tree is also known as 'bow wood' in Portuguese (pau d'arco) due to its historically dense, durable timber used for hunting bows.

Historical & Cultural Context

Indigenous peoples of South America, including the Incas and various Amazonian tribes, have used the inner bark of Tabebuia species for centuries, preparing it as a decoction called 'taheebo' or 'lapacho' to treat infections, fevers, inflammation, pain, and conditions including herpes, leukemia, and polio. In Brazil, the tree's name reflects its practical cultural significance as 'bow wood,' underscoring its dual role as both a utilitarian timber and medicinal resource. The bark gained widespread popularity in North American and European alternative medicine markets during the 1970s and 1980s following reports of its use by Brazilian healers and Andean shamans, leading to commercial export and incorporation into herbal supplement lines. Traditional preparation universally emphasizes use of the phloem (inner bark) rather than the outer bark or heartwood, a distinction that modern phytochemical analysis has validated as critical for maximizing bioactive naphthoquinone content.

Health Benefits

- **Antifungal Activity**: Lapachol and beta-lapachone disrupt cellular function in Candida and Aspergillus species in vitro, inhibiting fungal replication; however, clinical trials confirming this effect in humans are absent.
- **Antimicrobial Potential**: In vitro studies demonstrate activity against Staphylococcus aureus and Helicobacter pylori via inhibition of DNA synthesis; no human trials have confirmed therapeutic doses or clinical endpoints.
- **Anti-inflammatory Effects**: Beta-lapachone downregulates cyclooxygenase-2 (COX-2) expression and upregulates the Nrf2 pathway, reducing oxidative stress and inflammatory mediator production in preclinical models.
- **Antioxidant Support**: The bark contains quercetin, selenium, and phenolic compounds shown to neutralize reactive oxygen species; methanolic extracts and syrups exhibit the highest measurable antioxidant activity in laboratory assays.
- **Preliminary Anticancer Properties**: Beta-lapachone inhibits telomerase activity and induces apoptosis in tumor cell lines in animal models, with metastasis inhibition observed in murine studies; human efficacy data are lacking.
- **Pain Relief in Dysmenorrhea**: Preliminary clinical findings suggest pau d'arco preparations may reduce pain in primary dysmenorrhea, likely through COX-2 inhibition; specific sample sizes and effect sizes have not been published.
- **Oral Mucositis Prevention**: Early clinical observations indicate potential benefit in reducing oral mucositis severity in head and neck cancer patients undergoing radiotherapy, though these findings are uncontrolled and require validation.

How It Works

Lapachol and beta-lapachone, the primary naphthoquinone constituents of Tabebuia impetiginosa inner bark, exert antimicrobial and antiviral effects by inhibiting viral reverse transcriptase and interfering with DNA and RNA synthesis in susceptible microorganisms. Beta-lapachone specifically downregulates cyclooxygenase-2 (COX-2) gene expression, reducing prostaglandin synthesis and dampening inflammatory cascades, while also suppressing telomerase activity in cancer cell lines, impairing their replicative immortality. The Nrf2 (nuclear factor erythroid 2-related factor 2) signaling pathway is upregulated by beta-lapachone, leading to increased transcription of cytoprotective and antioxidant proteins including heme oxygenase-1 and superoxide dismutase. Quercetin and selenium contribute additive antioxidant activity by scavenging free radicals and supporting glutathione peroxidase function, complementing the naphthoquinone-mediated mechanisms.

Scientific Research

The body of evidence for Pau d'Arco consists predominantly of in vitro cell culture studies and murine animal models, with a very limited number of uncontrolled or poorly characterized human clinical observations. No large-scale, adequately powered randomized controlled trials (RCTs) have been published for any indication—antifungal, anticancer, anti-inflammatory, or analgesic—as of current available literature. A human trial evaluating lapachol in chronic myelocytic leukemia patients found no clinically meaningful effect, and the trial lacked published sample size or statistical detail. Preliminary human observations regarding oral mucositis prevention in radiotherapy patients and dysmenorrhea pain reduction are hypothesis-generating at best and cannot support clinical recommendations without controlled replication.

Clinical Summary

Clinical investigation of Pau d'Arco in humans is sparse and of low methodological quality, with no published RCTs meeting modern standards for any primary indication. The most notable human data involve lapachol's failure to produce clinical benefit in a leukemia patient cohort, and uncontrolled observations of possible mucositis reduction in radiotherapy settings and pain relief in primary dysmenorrhea. No quantified effect sizes, confidence intervals, or standardized outcome measures have been reported in accessible literature. Overall, confidence in clinical efficacy is very low; existing evidence does not support therapeutic use for any condition pending rigorous controlled trials.

Nutritional Profile

Pau d'Arco inner bark is not consumed as a conventional food and does not contribute meaningful macronutrients (protein, fat, or carbohydrate) to the diet in typical supplemental quantities. Its primary phytochemical constituents include naphthoquinones—lapachol and beta-lapachone—as well as quinoids, benzenoids, the flavonoid quercetin, and phenolic compounds; precise concentration ranges per gram of bark are not established in standardized pharmacopeial references due to variability by geographic source and bark quality. Selenium is present in measurable but unquantified amounts, contributing to antioxidant capacity alongside the phenolic fraction. Phenolic and flavonoid content is highest in methanolic extracts and syrup preparations compared to aqueous teas, and bioavailability of lapachol in humans is poorly characterized; whole bark products have substantially diluted naphthoquinone concentrations relative to inner phloem-exclusive preparations.

Preparation & Dosage

- **Tea (Traditional)**: Simmer 1–2 teaspoons (approximately 2–4 g) of dried inner bark (phloem only) in 500 mL water for 20 minutes; consume 1–3 cups daily. Prioritize phloem-exclusive bark for higher naphthoquinone potency.
- **Capsules/Tablets**: Commercial preparations typically range from 300–500 mg per capsule; no clinically validated dose exists. Products standardized to lapachol content are preferable but not universally available.
- **Liquid Extract/Tincture**: Typically dosed at 1–2 mL (1:5 tincture) two to three times daily; methanolic and ethanol extracts show higher phenolic and flavonoid concentrations than aqueous teas.
- **Syrup**: Standardized syrups have demonstrated higher antioxidant activity in laboratory testing; dosing protocols are not established in clinical literature.
- **Topical Application**: Applied as a poultice or diluted extract to skin lesions; no reliable safety or efficacy data support specific concentrations or duration.
- **Standardization Note**: No international pharmacopeial standard for lapachol or naphthoquinone content exists; whole bark products dilute active compound concentration relative to inner phloem-only preparations.

Synergy & Pairings

Pau d'Arco is traditionally combined with other antimicrobial herbs such as cat's claw (Uncaria tomentosa), where overlapping anti-inflammatory and immunomodulatory mechanisms may provide additive benefit; however, no controlled data confirm enhanced efficacy from this pairing. The quercetin content of Pau d'Arco may synergize with vitamin C to enhance antioxidant recycling and phenolic bioavailability, a well-documented mechanism in flavonoid pharmacology. In traditional Amazonian formulations, pau d'arco is occasionally combined with muira puama or suma root in adaptogenic blends, though the mechanistic basis and clinical relevance of these combinations are not supported by published evidence.

Safety & Interactions

Pau d'Arco is classified as possibly unsafe when taken orally, particularly at elevated doses; adverse effects attributable to lapachol include severe nausea, vomiting, diarrhea, dizziness, and internal bleeding, with reproductive toxicity (including potential teratogenicity) reported in preclinical models. Safety at conventionally marketed tea or capsule doses is not established, as no dose-ranging safety studies in humans have been published, and the doses required to replicate in vitro anticancer effects are considered clinically toxic. Drug interaction data are not formally characterized, but lapachol's structural similarity to vitamin K antagonists raises a plausible anticoagulant interaction risk with warfarin and other blood thinners; immunomodulatory effects may also interfere with immunosuppressive medications. Pau d'Arco is contraindicated in pregnancy and lactation based on reproductive toxicity signals, and should be avoided by individuals on anticoagulant therapy; topical use lacks sufficient safety data to establish a reliable risk profile.